Article Text

Download PDFPDF
Thrombin-activatable fibrinolysis inhibitor and its relation with inflammation in rheumatoid arthritis
  1. M J L Peters1,
  2. M T Nurmohamed1,2,
  3. I C van Eijk2,
  4. C J N Verkleij3,
  5. P F Marx3
  1. 1
    Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands
  2. 2
    Department of Rheumatology, Jan van Breemen Institute, Amsterdam, The Netherlands
  3. 3
    Department of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
  1. P F Marx, Academic Medical Center, Department of Experimental Vascular Medicine, Meibergdreef 9, 1105 AZ (Room G1-145), Amsterdam, The Netherlands; p.f.marx{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Rheumatoid arthritis (RA) is associated with an excessive risk of cardiovascular morbidity and mortality, and inflammation appears to be the missing link explaining this markedly elevated risk.1 Inflammation is a potent inducer of coagulation and fibrinolysis and may contribute to atherosclerotic and thrombotic components of cardiovascular events.2 Thrombin-activatable fibrinolysis inhibitor (TAFI), a procarboxypeptidase in plasma, is a regulatory protein of the coagulation/fibrinolysis balance as well as inflammation. TAFIa, the activated form of TAFI, acts by removing C-terminal arginine and lysine residues from substrates such as fibrin degradation products, bradykinin and the anaphylatoxins C3a and C5a. Elevated TAFI levels may reflect an enhanced risk of developing cardiovascular …

View Full Text


  • Competing interests: None declared.

  • Ethics approval: The local ethics committees approved the study protocol and all participants provided written informed consent.